Envelope protein Molekülinformation
Molecule Name
Recombinant envelope protein
Molekülalias
Envelope protein,Env polyprotein,Envelope glycoprotein,env
Drug Development Progress
Anzahl der klinischen Arzneimittel6
Anzahl der inverkehr gebrachten Arzneimittel1
Höchste Forschungs- und EntwicklungsphaseApproved
Target-Alias
env，Submitted name: Recombinant envelope protein，Viral Envelope Proteins
Molekülhintergrund
The SARS-CoV-2 is composed of a double-layered lipid envelope, including Spike glycoprotein (S), Envelope protein (E), Membrane glycoprotein (M), and Nucleocapsid protein (Nucleocapsid protein, N). Among them, The amino acid sequence of the SARS-CoV-2 envelope protein is 95% identical of the SARS envelope protein.
Envelope protein Produktliste
You Have Viewed 0 Of 0 Results
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Targeting HIV-1 Env gp140 antibodies | Phase 2 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid) | HIV Infections | Details | |
| Temelimab | GNN-001; GENHP-01; GNbAC-1 | Phase 2 Clinical | Geneuro Sa | Diabetes Mellitus, Type 1; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Post-Acute COVID-19 Syndrome | Details |
| VIS-513 | VIS-513; Ab-513 | Phase 2 Clinical | Otsuka Pharmaceutical Co Ltd, Serum Institute Of India Ltd, Visterra Inc | Dengue | Details |
| PGDM-1400 | PGDM-1400; PGDM1400LS | Phase 2 Clinical | International Aids Vaccine Initiative | Acquired Immunodeficiency Syndrome; HIV Infections; Sexually Transmitted Diseases, Viral | Details |
| MGD-020 | MGD020 | Phase 1 Clinical | Macrogenics Inc | HIV Infections | Details |
| GS-8588 | GS-8588 | Phase 1 Clinical | Gilead Sciences Inc | HIV Infections | Details |
Inverkehr gebrachte Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Frühestes Markenname | Frühestes Genehmigungsland | Früheste Indikation | Früheste Genehmigungsgesellschaft | Früheste Genehmigungsdatum | Indikationen | Klinische Studie |
|---|---|---|---|---|---|---|---|---|---|---|
| Tecovirimat | SIGA-246; ST-246 | Approved | Siga Technologies Inc | Tpoxx, Arestvyr | United States | Smallpox | Siga Technologies Inc | 2018-07-13 | Cowpox; Monkeypox; Orthopoxvirus Infection; Poxviridae Infections; Smallpox; Vaccinia | Details |